Compare Stocks → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYTRNASDAQ:ENTXOTCMKTS:ENZNOTCMKTS:MYMXOTCMKTS:OMBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsENTXEntera Bio$1.67+8.4%$1.17$0.52▼$1.87$44.36M1.68203,592 shs124,619 shsENZNEnzon Pharmaceuticals$0.09$0.08$0.06▼$0.26N/A0.2833,860 shsN/AMYMXMymetics$0.01$0.10$0.01▼$70.00N/A1.7411 shsN/AOMBPOmni Bio Pharmaceutical$0.00$0.00$0.00▼$0.04N/AN/AN/AN/ABeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTRLadRx0.00%0.00%0.00%0.00%0.00%ENTXEntera Bio+8.44%-2.91%+62.93%+178.33%+23.70%ENZNEnzon Pharmaceuticals0.00%+18.13%+18.13%+1.02%-57.72%MYMXMymetics0.00%0.00%0.00%+525.00%-54.55%OMBPOmni Bio Pharmaceutical0.00%0.00%0.00%0.00%0.00%“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/AENTXEntera Bio2.0097 of 5 stars3.53.00.00.02.81.70.0ENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMYMXMymeticsN/AN/AN/AN/AN/AN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTRLadRxN/AN/AN/AN/AENTXEntera Bio3.00Buy$10.00498.80% UpsideENZNEnzon PharmaceuticalsN/AN/AN/AN/AMYMXMymeticsN/AN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTRLadRxN/AN/AN/AN/AN/AN/AENTXEntera Bio$130K369.97N/AN/A$0.36 per share4.64ENZNEnzon Pharmaceuticals$30KN/AN/AN/AN/AN/AMYMXMymetics$1.08M0.00N/AN/A($0.23) per share-0.04OMBPOmni Bio PharmaceuticalN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/AENTXEntera Bio-$8.89M-$0.31N/A∞N/AN/A-101.78%-83.90%5/3/2024 (Estimated)ENZNEnzon Pharmaceuticals$1.37M$0.019.46∞N/AN/A46.47%2.92%N/AMYMXMymetics-$5.06M-$0.04N/A∞N/A-1,914.40%N/A-128.84%N/AOMBPOmni Bio PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTRLadRxN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AMYMXMymeticsN/AN/AN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTRLadRxN/AN/AN/AENTXEntera BioN/A10.3210.32ENZNEnzon PharmaceuticalsN/A27.6227.62MYMXMymeticsN/AN/AN/AOMBPOmni Bio PharmaceuticalN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTRLadRxN/AENTXEntera Bio14.11%ENZNEnzon PharmaceuticalsN/AMYMXMymetics0.73%OMBPOmni Bio PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipCYTRLadRxN/AENTXEntera Bio8.90%ENZNEnzon Pharmaceuticals0.27%MYMXMymetics5.13%OMBPOmni Bio PharmaceuticalN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableENTXEntera Bio1928.80 million26.24 millionOptionableENZNEnzon PharmaceuticalsN/AN/AN/ANot OptionableMYMXMymetics2150,000144,000Not OptionableOMBPOmni Bio Pharmaceutical1N/AN/ANot OptionableENZN, CYTR, ENTX, MYMX, and OMBP HeadlinesSourceHeadlineZhejiang Wolwo Bio-Pharmaceutical Co Ltd Class Amorningstar.com - March 2 at 8:10 PMShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349)investing.com - December 2 at 10:18 AMShanxi Jinbo Bio pharmaceutical Co Ltd 832982morningstar.com - November 12 at 12:55 PMOversold Conditions For BridgeBio Pharma (BBIO)nasdaq.com - October 6 at 5:14 PMSinopep Allsino Bio Pharmaceutical Co Ltd Class Amorningstar.com - August 24 at 6:56 PMOmni-Crawlerhackaday.com - June 29 at 10:09 AMShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.wsj.com - May 16 at 9:00 AM2023 Bio Pharma Logistics Market | Dynamic Report By 2030marketwatch.com - April 22 at 12:16 AMShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Class Hmorningstar.com - April 21 at 8:43 AMBio-pharma Market Key Players and Forecast till 2031marketwatch.com - March 31 at 8:55 AM2023 Bio Pharma Logistics Market Size, Growth | Global Industry Trends [2029]marketwatch.com - March 29 at 6:06 PMMy Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conferencethestreet.com - March 25 at 11:55 PMZhejiang Wolwo Bio Pharmaceutical Co. Ltd.wsj.com - March 22 at 6:47 PMSanofi’s $2.9B deal for Provention Bio to bolster diabetes treatment offeringsmmm-online.com - March 13 at 8:57 PMZhejiang Wolwo Bio-Pharmaceutical Co Ltd Class A 300357 Stock Quotemorningstar.com - February 22 at 12:03 AMBio Pharma Logistics Market [Latest Report ]2023 is Booming with Figures, Sales Volume, Financial Barriers and Outlook to 2027marketwatch.com - January 27 at 3:35 PMBioMarin Pharmaceuticalforbes.com - January 5 at 2:43 PMZhejiang Wolwo Bio-Pharmaceutical Co Ltdreuters.com - October 7 at 3:51 PMSinopep Allsino Bio Pharmaceutical Co Ltd (688076)investing.com - September 22 at 1:03 PMSlingshot Biosciences, Inc. Partners with OLS – OMNI Life Science to Distribute Synthetic Cells Throughout Germany, Austria, Switzerland, and Italyapnews.com - July 8 at 3:47 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsLadRxNASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Entera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Enzon PharmaceuticalsOTCMKTS:ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.MymeticsOTCMKTS:MYMXMymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.Omni Bio PharmaceuticalOTCMKTS:OMBPOmni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.